Oliceridine Matches Remifentanil Analgesia in Ventilated ICU Patients, With Fewer Post-Extubation Respiratory Events
CO-ROAM is the first randomized comparison of the G protein-biased opioid oliceridine against remifentanil in mechanically ventilated adults, and it gives ICU pharmacists early data on analgesia-first protocols and ventilator liberation.
📅 Journal publication: Nov 10, 2026·Last updated: Nov 16, 2026
Oliceridine matches remifentanil's analgesia with enhanced safety in the ICU.
Analgesic management during mechanical ventilation is crucial for patient safety and comfort. Oliceridine showed a non-inferior analgesic effect to remifentanil with fewer adverse drug reactions and respiratory issues. This study suggests oliceridine as a potential alternative to remifentanil, with a better safety profile in managing pain for ventilated patients. Oliceridine offers effective analgesia with fewer adverse effects compared to remifentanil in ICU settings.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Lu S, Luo JC, Li Q, Lei XY, Ding XF, Dong QL, Hu QH, Zhu WT, Zhang X, Duan LL, Lv S, Ran QF, Ma L, Guo C, Dong JJ, Yang YQ, Xu L, Yang J, Wang J, Qiu LF, Jing BC, Jia FJ, Zhang L, Tang QB, Ibarra-Estrada M, Luo MH, Pan C, Huang XB, Martin-Loeches I
Citation:Lu S, Luo JC, Li Q, et al. Efficacy and safety of oliceridine versus remifentanil for analgesia in mechanically ventilated critically ill adults (CO-ROAM): a multicenter, assessor-blinded, non-inferiority randomized controlled trial. Intensive care medicine. 2026. doi:10.1007/s00134-026-08643-8